Amid leadership changes and anti-trust scrutiny, Illumina has lowered its 2023 guidance. The company now expects a 1% increase in revenue, down from its previous 7% to 10% growth forecast.

While GlaxoSmithKline is anticipating a slower uptake of respiratory syncytial virus vaccine Arexvy, CEO Emma Walmsley said Wednesday the company is pinning much of its growth on the vaccine’s performance.